Evidence map›Paper›PMID 36280849›Full record

ArticleArthritis research & therapy2022

Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment.

Giacomo Cafaro, Eleonora Petito, Onelia Bistoni, Emanuela Falcinelli, Sabrina Cipriani, Maria Chiara Borghi, Angelo F Bonifacio, Elisa Giglio, Alessia Alunno, Carlo Perricone and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Giacomo Cafaro *Rheumatology Unit, University of Perugia, Perugia, Italy.
Eleonora Petito *Section of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Onelia BistoniRheumatology Unit, University of Perugia, Perugia, Italy.
Emanuela FalcinelliSection of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Sabrina CiprianiRheumatology Unit, University of Perugia, Perugia, Italy.
Maria Chiara BorghiSection of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Angelo F BonifacioRheumatology Unit, University of Perugia, Perugia, Italy.
Elisa GiglioSection of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Alessia AlunnoRheumatology Unit, University of Perugia, Perugia, Italy.
Carlo PerriconeRheumatology Unit, University of Perugia, Perugia, Italy.
Roberto GerliRheumatology Unit, University of Perugia, Perugia, Italy. roberto.gerli@unipg.it.
Paolo Gresele *Section of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Elena Bartoloni *Rheumatology Unit, University of Perugia, Perugia, Italy.
University of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndothelial dysfunction contributes to increased cardiovascular (CV) disease in rheumatoid arthritis (RA). Angiogenic T cells (Tang) are a key regulator of vascular function via their interaction with endothelial progenitor cells (EPCs). Methotrexate (MTX) has been associated to reduced CV disease risk, but its effects on endothelial homeostasis have been poorly explored. We investigated MTX effects on endothelial homeostasis in early, treatment-naïve RA patients.

methodsFifteen untreated, early RA patients and matched healthy controls (HC) were enrolled. RA patients with long-standing disease in remission or low disease activity treated with MTX for at least 6 months were selected as controls. Circulating CD28

resultsTang percentage was higher in early RA than in HCs and significantly increased after 3-month MTX treatment. Tang cells in RA were characterized by higher percentage of CD28

conclusionsMTX has a positive effect on Tang, sVCAM-1, EPCs and EMPs in RA. Restoration of imbalance between CD28 + and CD28

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiomarkersCD28 AntigensEndotheliumHumansMethotrexateVascular Cell Adhesion Molecule-1Antirheumatic AgentsBiomarkersCD28 AntigensMethotrexateVascular Cell Adhesion Molecule-1Angiogenic T cellsCardiovascular diseaseEndothelial dysfunctionMethotrexateMicrovesiclesPlateletsRheumatoid arthritis

Identifiers

PMID36280849
PMCPMC9590167
OpenAlexW4307127946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.